Praxis Precision Medicines. has filed a patent for compounds and compositions that can be used to prevent and treat neurological diseases, excessive neuronal excitability, and gain-of-function mutations in genes such as KCNT1. The patent also includes a pharmaceutical composition comprising a specific compound formula. GlobalData’s report on Praxis Precision Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Praxis Precision Medicines Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Praxis Precision Medicines, Peptide pharmacophores was a key innovation area identified from patents. Praxis Precision Medicines's grant share as of September 2023 was 13%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230285377A1) describes a pharmaceutical composition comprising a compound with a specific chemical formula. The composition includes a compound with Formula A, where X is CR7 or N and Y is S, or X is CR7 and Y is O. The composition also includes a ring A, which can be phenyl, 6-membered heteroaryl, or 5-7 membered heterocyclyl. Additionally, the composition includes various substituents and groups, such as R1, R2, R3, R4, R5, R6, R7, R8, and R9, which can be selected from specific groups and atoms. The composition can be in the form of a pharmaceutically acceptable salt and is combined with a pharmaceutically acceptable carrier.

Another aspect of the patent describes a pharmaceutical composition comprising a compound with Formula A-1, which has similar characteristics to the compound described above. However, in this case, ring A is specifically a 6-membered heteroaryl. The composition also includes various substituents and groups, similar to the previous composition.

The patent also mentions the use of the compound in the treatment of neurological diseases or disorders, diseases or conditions associated with excessive neuronal excitability, and diseases or conditions associated with gain-of-function mutations of specific genes, such as KCNT1. The compound can be administered to a subject in need of treatment in an effective amount, either alone or as part of a pharmaceutical composition.

Overall, the patent describes specific pharmaceutical compositions comprising compounds with defined chemical formulas and their potential use in the treatment of various neurological diseases and disorders.

To know more about GlobalData’s detailed insights on Praxis Precision Medicines, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies